Cognitive dysfunction and dementia in Parkinson's disease

Journal of Neural Transmission

Volumn 111, Issue 10-11, 2004, Pages 1303-1315

  Bosboom, J L W ^a   Stoffers, D ^a,b   Wolters, E Ch ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cognition; Dementia; Parkinson's disease

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; BRAIN CORTEX; CAREGIVER; CAUDATE NUCLEUS; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISTRESS SYNDROME; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; HUMAN; LOCUS CERULEUS; MEYNERT BASAL NUCLEUS; MOTOR DYSFUNCTION; NAUSEA; NERVE DEGENERATION; NERVE PROJECTION; NURSING HOME; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEROTONINERGIC NERVE CELL; SIDE EFFECT; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TREATMENT OUTCOME; VENTRAL TEGMENTUM; VOMITING;

COGNITION DISORDERS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 7944233769     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0168-1     Document Type: Review

References (123)

1. Aarsland D, Tandberg E, Larsen JP, Cummings JL (1996) Frequency of dementia in Parkinson disease. Arch Neurol 53: 538-542
2. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999) Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14: 866-874
3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48: 938-942
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 56: 730-736
5. Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72: 708-712
6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003a) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387-392
7. Aarsland D, Hutchinson M, Larsen JP (2003b) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 937-941
8. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP (2003c) Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 1215-1220
9. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357-381
10. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington DC
11. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59: 102-112
12. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, Jaros E, O'Brien J, Holmes C, Perry E (2000) Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 48: 868-876
13. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59: 1714-1720
14. Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y (1999) Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcorticofrontal syndrome. Brain Cogn 40: 289-313
15. Bergman J, Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25: 107-110
16. Boller F, Passafiume D, Keefe NC, Rogers K, Morrow L, Kim Y (1984) Visuospatial impairment in Parkinson's disease. Role of perceptual and motor factors. Arch Neurol 41: 485-490
17. Bondi MW, Kaszniak AW, Bayles KA, Vance KT (1993) Contribution of frontal system dysfunction to memory and perceptual abilities in Parkinson's disease. Neuropsychology 7: 89-102
18. Bosboom JLW, Wolters EC (2004) Psychotic symptoms in Parkinson's disease: pathophysiology and management. Exp Opinion Drug Saf 3: 209-220
19. Bowen FP, Hoehn MM, Yahr MD (1972) Parkinsonism: alterations in spatial orientation as determined by a route-walking test. Neuropsychologia 10: 355-361
20. Bowen FP, Kamienny RS, Burns MM, Yahr M (1975) Parkinsonism: effects of levodopa treatment on concept formation. Neurology 25: 701-704
21. Bradley VA, Welch JL, Dick DJ (1989) Visuospatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 52: 1228-1235
22. Brown RG, Marsden CD (1986) Visuospatial function in Parkinson's disease. Brain 109 (Pt 5): 987-1002
23. Bullock R, Cameron A (2002) Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 18: 258-264
24. Burn DJ, McKeith IG (2003a) Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 18 [Suppl 6]: S72-S79
25. Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, Thomas A, Newby J, Reid J, O'Brien JT, McKeith IG (2003b) Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 18: 884-889
26. Buytenhuijs EL, Berger HJ, van Spaendonck KP, Horstink MW, Borm GF, Cools AR (1994) Memory and learning strategies in patients with Parkinson's disease. Neuropsychologia 32: 335-342
27. Cash R, Dennis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 37: 42-46
28. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287: 373-392
29. Connor DJ, Salmon DP, Sandy TJ, Galasko D, Hansen LA, Thal LJ (1998) Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 55: 994-1000
30. Cooper JA, Sagar HJ (1993) Encoding deficits in untreated Parkinson's disease. Cortex 29: 251-265
31. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 115 (Pt 6): 1701-1725
32. Cooper JA, Sagar HJ, Tidswell P, Jordan N (1994) Slowed central processing in simple and go/no-go reaction time tasks in Parkinson's disease. Brain 117 (Pt 3): 517-529
33. Cummings JL (1993) Frontal-subcortical circuits and human behavior. Arch Neurol 50: 873-880
34. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B (1998) Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 50: 1214-1221
35. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403
36. de Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45: 1161-1164
37. de Vos RA, Jansen EN, Stam FC, Ravid R, Swaab DF (1995) 'Lewy body disease': clinicopathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 97: 13-22
38. Dubois B, Pillon B (1997) Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8
39. Elizan TS, Sroka H, Maker H, Smith H, Yahr MD (1986) Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients. J Neural Transm 65: 285-302
40. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 23: 41-43
41. Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123 (Pt 4): 733-745
42. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147
43. Gabelli C (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr Med Res Opin 19: 69-82
44. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 108: 368-373
45. Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, Caraceni T (1988) Dementia and cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 1498-1502
46. Goldman-Rakic PS (1987) Circuitry of primate prefrontal cortex and regulation of behavior by representational memory. In: Plum F, Mountcastle U (eds) Handbook of physiology. The American Physiological Society, Washington, pp 373-417
47. Gotham AM, Brown RG, Marsden CD (1988) 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 111 (Pt 2): 299-321
48. Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG (2001) Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr 13: 199-205
49. Harding AJ, Halliday GM (2001) Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 102: 355-363
50. Hovestadt A, De Jong GJ, Meerwaldt JD (1987) Spatial disorientation as an early symptom of Parkinson's disease. Neurology 37: 485-487
51. Huber SJ, Shuttleworth EC, Freidenberg DL (1989) Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases. Arch Neurol 46: 1287-1291
52. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54: 1596-1602
53. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, Arnold SE (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54: 1916-1921
54. Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61: 324-325
55. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R (1995) Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 45: 1691-1696
56. Jellinger KA (1999) Neuropathological correlates of mental dysfunction in Parkinson's disease: an update. In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II. APP, Utrecht, pp 82-105
57. Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109: 329-339
58. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40: 399-410
59. Kulisevsky J (2000a) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 16: 365-379
60. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000b) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15: 613-626
61. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM (1992) L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 107: 394-404
62. Lange KW, Paul GM, Naumann M, Gsell W (1995) Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm [Suppl] 46: 423-432
63. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2000) Motor impairment in PD: relationship to incident dementia and age. Neurology 55: 539-544
64. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2002) Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 17: 1221-1226
65. Lewis SJG, Dove A, Robbins TW, Barker RA, Owen AM (2004) Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci 19: 755-760
66. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55: 969-978
67. Mahieux F, Fenelon G, Flahault A, Manifacier MJ, Michelet D, Boller F (1998) Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 64: 178-183
68. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 52: 695-701
69. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO (1998) Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl) 95: 576-582
70. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M (2000) Alpha-synuclein-immuno-reactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 100: 285-290
71. Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO (2001) Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol (Berl) 102: 160-166
72. Mayeux R, Stern Y, Sano M, Cote L, Williams JB (1987) Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 37: 1130-1134
73. Mayeux R, Stern Y, Rosenstein R, Marder K, Hauser A, Cote L, Fahn S (1988) An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol 45: 260-262
74. Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, Cote L, Stern Y (1990) An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 40: 1513-1517
75. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 49: 492-497
76. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124
77. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000a) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036
78. McKeith IG (2000b) Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin 18: 865-902
79. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000c) Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15: 387-392
80. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983a) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214: 170-197
81. Mesulam MM, Mufson EJ, Wainer BH, Levey AI (1983b) Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10: 1185-1201
82. Oades RD, Halliday GM (1987) Ventral segmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res 434: 117-165
83. Ogden JA, Growdon JH, Corkin S (1990) Deficits on visuospatial tests involving forward planning in high-functioning Parkinsonians. Neuropsychiatr Neuropsychol Behav Neurol 3: 125-139
84. Owen AM, Beksinska M, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Sahakian BJ, Robbins TW (1993) Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 31: 627-644
85. Owen AM, Iddon JL, Hodges JR, Summers BA, Robbins TW (1997) Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia 35: 519-532
86. Owen AM, Doyon J, Dagher A, Sadikot A, Evans AC (1998) Abnormal basal ganglia outflow in Parkinson's disease identified with PET. Implications for higher cortical functions. Brain 121 (Pt 5): 949-965
87. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 50: 743-755
88. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-421
89. Perry EK, McKeith I, Thompson P, Marshall E, Kerwin J, Jabeen S, Edwardson JA, Ince P, Blessed G, Irving D (1991) Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann NY Acad Sci 640: 197-202
90. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ, Ince PG, Brown A, Perry RH (1992) Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 13: 393-400
91. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AF, Ince PG, Morris CM, Cheng AV (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79
92. Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y (1989) Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 52: 201-206
93. Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 50: 374-379
94. Pillon B, Deweer B, Vidailhet M, Bonnet AM, Hahn-Barma V, Dubois B (1998) Is impaired memory for spatial location in Parkinson's disease domain specific or dependent on 'strategic' processes? Neuropsychologia 36: 1-9
95. Pillon B, Boller F, Levy R, Dubois B (2001) Cognitive deficits and dementia in Parkinson's disease. In: Boller F, Cappa S (eds) Aging and dementia, vol 6. Elsevier Science B.V., Amsterdam, pp 311-371
96. Poewe W (2003) Psychosis in Parkinson's disease. Mov Disord 18 [Suppl 6]: S80-S87
97. Ransmayr G, Schmidhuber-Eiler B, Karamat E, Engler-Plorer S, Poewe W, Leidlmair K (1987) Visuoperception and visuospatial and visuorotational performance in Parkinson's disease. J Neurol 235: 99-101
98. Raskin SA, Borod JC, Tweedy JR (1992) Set-shifting and spatial orientation in patients with Parkinson's disease. J Clin Exp Neuropsychol 14: 801-821
99. Read NL, Hughes TA, Dunn EM, Nirodi P, Branton T, Mindham RH, Spokes EG (2001) Dementia in Parkinson's disease: incidence and associated factors at 14-years of follow-up. Parkinsonism and Related Disorders 7: S109
100. Reading PJ, Luce AK, McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1174
101. Richard IH, Papka M, Rubio A, Kurlan R (2002) Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 17: 1161-1165
102. Rinne JO, Rummukainen J, Paljarvi L, Rinne UK (1989) Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26: 47-50
103. Rogers RD, Sahakian BJ, Hodges JR, Polkey CE, Kennard C, Robbins TW (1998a) Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson's disease. Brain 121 (Pt 5): 815-842
104. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998b) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145
105. Rowe J, Stephan KE, Friston K, Frackowiak R, Lees A, Passingham R (2002) Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 125: 276-289
106. Samochocki M, Zerlin M, Jostock R, Groot Kormelink PJ, Luyten WH, Albuquerque EX, Maelicke A (2000) Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand [Suppl] 176: 68-73
107. SantaCruz K, Pahwa R, Lyons K, Troster A, Handler M, Koller W, DeCarli C (1999) Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology 52: A476-A477
108. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321-328
109. Scheltens Ph (1999) Dementia in Parkinon's disease: subclinical Alzheimer's disease? In: Wolters ECh, Scheltens Ph, Berendse HW (eds) Mental dysfunctions in Parkinson's disease II. APP, Utrecht, pp 189-193
110. Smith EE, Jonides J (1999) Storage and executive processes in the frontal lobes. Science 283: 1657-1661
111. Smith MC, Goldman WP, Janer KW, Baty JD, Morris JC (1998) Cognitive speed in nondemented Parkinson's disease. J Int Neuropsychol Soc 4: 584-592
112. Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 43: 1690-1692
113. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000) A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine US A-10 Study Group. Neurology 54: 2269-2276
114. Taylor AE, Saint-Cyr JA, Lang AE (1986) Frontal lobe dysfunction in Parkinson's disease. The cortical focus of neostriatal outflow. Brain 109: 845-883
115. Taylor AE, Saint-Cyr JA, Lang AE (1990) Memory and learning in early Parkinson's disease: evidence for a "frontal lobe syndrome". Brain Cogn 13: 211-232
116. Thierry AM, Tassin JP, Blanc G, Glowinski J (1978) Studies on mesocortical dopamine systems. Adv Biochem Psychopharmacol 19: 205-216
117. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411
118. Werber EA, Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325
119. Whitehouse PJ, Hedreen JC, White CL, III, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13: 243-248
120. Wilson RS, Kaszniak AW, Klawans HL, Garron DC (1980) High speed memory scanning in parkinsonism. Cortex 16: 67-72
121. Wolters EC (2001) Psychiatric complications in the treatment of Parkinson's disease. Adv Neurol 86: 385-393
122. Wolters EC, Francot CMJE (1998) Mental dysfunctions in Parkinson's disease. Parkinsonism Rel Disord 4: 107-112
123. Woods SP, Troster AI (2003) Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 9: 17-24